

Adrian G Sacher

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1372495/adrian-g-sacher-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

62

papers

2,651

citations

21

h-index

51

g-index

67

ext. papers

3,769

ext. citations

7

avg, IF

5.15

L-index

#	Paper	IF	Citations
62	Integrating comprehensive genomic sequencing of non-small cell lung cancer into a public healthcare system.. <i>Cancer Treatment and Research Communications</i> , 2022 , 31, 100534	2	1
61	Survival outcomes of metastatic renal cell carcinoma (mRCC) with sarcomatoid differentiation (SD): A single-institutional experience and literature meta-analysis.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 332-332	2.2	
60	New Strategies and Combinations to Improve Outcomes in Immunotherapy in Metastatic Non-Small-Cell Lung Cancer.. <i>Current Oncology</i> , 2021 , 29, 38-55	2.8	0
59	Genomic characterization of non-schistosomiasis-related squamous cell carcinoma of the urinary bladder: A retrospective exploratory study. <i>PLoS ONE</i> , 2021 , 16, e0259272	3.7	0
58	Chemical Genetics Screen Identifies COPB2 Tool Compounds That Alters ER Stress Response and Induces RTK Dysregulation in Lung Cancer Cells. <i>Journal of Molecular Biology</i> , 2021 , 433, 167294	6.5	2
57	Concurrent Chemoradiation With or Without Durvalumab in Elderly Patients With Unresectable Stage III NSCLC: Safety and Efficacy.. <i>JTO Clinical and Research Reports</i> , 2021 , 2, 100251	1.4	1
56	Durability of CNS disease control in NSCLC patients with brain metastases treated with immune checkpoint inhibitors plus cranial radiotherapy. <i>Lung Cancer</i> , 2021 , 156, 76-81	5.9	2
55	Sotorasib for Lung Cancers with p.G12C Mutation. <i>New England Journal of Medicine</i> , 2021 , 384, 2371-2381	39.2	168
54	Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castration-resistant prostate cancer treated with Radium-223. <i>Cancer Medicine</i> , 2021 , 10, 5775-5782	4.8	2
53	Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non-small cell lung cancer: A real-world multicentre study. <i>European Journal of Cancer</i> , 2021 , 142, 83-91	7.5	15
52	The impact of symptoms and comorbidity on health utility scores and health-related quality of life in small cell lung cancer using real world data. <i>Quality of Life Research</i> , 2021 , 30, 445-454	3.7	1
51	Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint Inhibitors. <i>Clinical Lung Cancer</i> , 2021 , 22, 253-259	4.9	17
50	Natural Killer Cells and Type 1 Innate Lymphoid Cells in Hepatocellular Carcinoma: Current Knowledge and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	3
49	Systemic Inflammatory Markers of Survival in Epidermal Growth Factor-Mutated Non-Small-Cell Lung Cancer: Single-Institution Analysis, Systematic Review, and Meta-analysis. <i>Clinical Lung Cancer</i> , 2021 , 22, 390-407	4.9	1
48	Prevalence and Heterogeneity of PD-L1 Expression by 22C3 Assay in Routine Population-Based and Reflexive Clinical Testing in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 1490-1500	8.9	3
47	The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2021 , 160, 136-151	5.9	10
46	Tobacco exposure and immunotherapy response in PD-L1 positive lung cancer patients. <i>Lung Cancer</i> , 2020 , 150, 159-163	5.9	10

45	BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer. <i>Lung Cancer</i> , 2020 , 146, 78-85	5.9	6
44	ALK-rearranged lung adenocarcinoma transformation into high-grade large cell neuroendocrine carcinoma: Clinical and molecular description of two cases. <i>Lung Cancer</i> , 2020 , 146, 350-354	5.9	5
43	A drug discovery platform to identify compounds that inhibit EGFR triple mutants. <i>Nature Chemical Biology</i> , 2020 , 16, 577-586	11.7	15
42	Early Detection of Multiple Resistance Mechanisms by ctDNA Profiling in a Patient With EGFR-mutant Lung Adenocarcinoma Treated With Osimertinib. <i>Clinical Lung Cancer</i> , 2020 , 21, e488-e492	4.9	2
41	EGFR-mutated lung adenocarcinomas from patients who progressed on EGFR-inhibitors show high engraftment rates in xenograft models. <i>Lung Cancer</i> , 2020 , 145, 144-151	5.9	2
40	Development of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs. <i>Cancer</i> , 2020 , 126, 1550-1558	6.4	9
39	Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomas. <i>Lung Cancer</i> , 2020 , 140, 35-41	5.9	12
38	Cytotoxic CD4 T Cells in Bladder Cancer-A New License to Kill. <i>Cancer Cell</i> , 2020 , 38, 28-30	24.3	7
37	KRAS Inhibition with Sotorasib in Advanced Solid Tumors. <i>New England Journal of Medicine</i> , 2020 , 383, 1207-1217	59.2	469
36	Real-world health utility scores and toxicities to tyrosine kinase inhibitors in epidermal growth factor receptor mutated advanced non-small cell lung cancer. <i>Cancer Medicine</i> , 2019 , 8, 7542-7555	4.8	6
35	The presence and variant allele fraction of EGFR mutations in ctDNA and development of resistance. <i>Lung Cancer</i> , 2019 , 131, 86-89	5.9	9
34	Financial Burden Among Patients With Lung Cancer in a Publically Funded Health Care System. <i>Clinical Lung Cancer</i> , 2019 , 20, 231-236	4.9	21
33	Non-small cell lung cancer (NSCLC) next generation sequencing (NGS) using the Oncomine Comprehensive Assay (OCA) v3: Integrating expanded genomic sequencing into the Canadian publicly funded health care model.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2620-2620	2.2	5
32	Phase I study of local radiation and tremelimumab in patients with inoperable locally recurrent or metastatic breast cancer. <i>Oncotarget</i> , 2019 , 10, 2947-2958	3.3	17
31	Feasibility study of microbial ecosystem therapeutics (MET-4) to evaluate effects of fecal microbiome in patients on immunotherapy (MET4-IO).. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS2664-TPS2664	2.3	2664
30	Myeloid immunosuppressive state as a predictor of rapidly progressive phenotype and poor survival in advanced non-small cell lung cancer (NSCLC) patients treated with PD-1/PD-L1 inhibitors.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e20594-e20594	2.2	
29	Comparing health utility scores, treatments, and outcomes in lung cancer patients with rare EGFR mutations with those with exon 19 deletion (del) and L858R mutations.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 102-102	2.2	
28	Monitoring of Response and Resistance in Plasma of EGFR-Mutant Lung Cancer Using Droplet Digital PCR. <i>Methods in Molecular Biology</i> , 2018 , 1768, 193-207	1.4	4

27	Fundamental Concepts in the Application of Plasma Genotyping (Liquid Biopsy) to Mutation Detection in Non-Small-Cell Lung Cancer.. <i>JCO Precision Oncology</i> , 2018 , 2, 1-12	3.6	
26	Co-clinical quantitative tumor volume imaging in ALK-rearranged NSCLC treated with crizotinib. <i>European Journal of Radiology</i> , 2017 , 88, 15-20	4.7	10
25	Application of Plasma Genotyping Technologies in Non-Small Cell Lung Cancer: A Practical Review. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 1344-1356	8.9	67
24	PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens. <i>Cancer Cytopathology</i> , 2017 , 125, 896-907	3.9	119
23	Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients. <i>Clinical Cancer Research</i> , 2016 , 22, 915-22	12.9	177
22	The promise and pitfalls of the many methods of plasma genotyping. <i>Expert Opinion on Biological Therapy</i> , 2016 , 16, 1313-1316	5.4	1
21	Talimogene laherparepvec (T-Vec) for the treatment of melanoma and other cancers. <i>Seminars in Oncology</i> , 2016 , 43, 638-646	5.5	38
20	Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A Review. <i>JAMA Oncology</i> , 2016 , 2, 1217-22	13.4	165
19	Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non-Small-Cell Lung Cancer. <i>JAMA Oncology</i> , 2016 , 2, 313-20	13.4	106
18	A window of opportunity study of potential tumor and soluble biomarkers of response to preoperative erlotinib in early stage non-small cell lung cancer. <i>Oncotarget</i> , 2016 , 7, 25632-9	3.3	6
17	Early Intervention in Lung Cancers With Rapid Plasma Genotyping for EGFR and KRAS Mutations-Reply. <i>JAMA Oncology</i> , 2016 , 2, 1096-7	13.4	10
16	Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer. <i>JAMA Oncology</i> , 2016 , 2, 1014-22	13.4	412
15	Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer. <i>Cancer Discovery</i> , 2016 , 6, 1334-1341	24.4	94
14	Real-world chemotherapy treatment patterns in metastatic non-small cell lung cancer: Are patients undertreated?. <i>Cancer</i> , 2015 , 121, 2562-9	6.4	56
13	Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non-small cell lung cancer. <i>Cancer</i> , 2014 , 120, 2289-98	6.4	25
12	Shifting patterns in the interpretation of phase III clinical trial outcomes in advanced non-small-cell lung cancer: the bar is dropping. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1407-11	2.2	36
11	Prediction of lung cancer genotype noninvasively using droplet digital PCR (ddPCR) analysis of cell-free plasma DNA (cfDNA).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8059-8059	2.2	1
10	Fulvestrant for advanced breast cancer: a meta-analysis. <i>Cancer Treatment Reviews</i> , 2013 , 39, 753-8	14.4	26

9	Elderly patients with advanced NSCLC in phase III clinical trials: are the elderly excluded from practice-changing trials in advanced NSCLC?. <i>Journal of Thoracic Oncology</i> , 2013 , 8, 366-8	8.9	72
8	Treatment of the elderly when cure is the goal: the influence of age on treatment selection and efficacy for stage III non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 537-44	8.9	44
7	Long-term survival of a patient with glioblastoma. <i>Canadian Journal of Neurological Sciences</i> , 2010 , 37, 289-92	1	2
6	Taking the stress out of morning report: an analytic approach to the differential diagnosis. <i>Journal of General Internal Medicine</i> , 2009 , 24, 747-51	4	10
5	New drugs for brain tumors? Insights from chemical probing of neural stem cells. <i>Medical Hypotheses</i> , 2009 , 72, 683-7	3.8	24
4	Identification of a bone marrow-derived epithelial-like population capable of repopulating injured mouse airway epithelium. <i>Journal of Clinical Investigation</i> , 2009 , 119, 336-48	15.9	106
3	Chemical genetics reveals a complex functional ground state of neural stem cells. <i>Nature Chemical Biology</i> , 2007 , 3, 268-73	11.7	135
2	Targeted cell replacement with bone marrow cells for airway epithelial regeneration. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2007 , 293, L740-52	5.8	81
1	In Faint Praise of the World Bank's Gender Development Policy. <i>Canadian Journal of Sociology</i> , 2005 , 30, 95-111	0.9	3